Best Biotech Stocks To Research – June 18th

Aptevo Therapeutics, Thermo Fisher Scientific, and SpringWorks Therapeutics are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that develop products and technologies based on biological processes, such as pharmaceuticals, gene therapies, diagnostic tools, and agricultural biotech. These companies typically invest heavily in research and development and often face binary outcomes—major breakthroughs or costly setbacks—making their stock prices relatively volatile. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Aptevo Therapeutics (APVO)

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Shares of Aptevo Therapeutics stock traded up $4.11 on Wednesday, hitting $6.93. 102,412,343 shares of the company traded hands, compared to its average volume of 500,067. The stock’s 50 day moving average price is $9.14 and its 200-day moving average price is $143.05. Aptevo Therapeutics has a 52 week low of $2.81 and a 52 week high of $485.37.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of TMO stock traded up $2.77 on Wednesday, hitting $393.03. The stock had a trading volume of 1,272,500 shares, compared to its average volume of 1,936,466. Thermo Fisher Scientific has a one year low of $385.68 and a one year high of $627.88. The business has a 50 day moving average price of $415.31 and a 200 day moving average price of $490.41. The company has a market cap of $148.36 billion, a PE ratio of 23.05, a P/E/G ratio of 2.14 and a beta of 0.78. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.

SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

NASDAQ SWTX traded down $0.06 during trading on Wednesday, reaching $46.81. 5,244,423 shares of the company’s stock traded hands, compared to its average volume of 2,419,547. The company’s 50 day simple moving average is $44.48 and its two-hundred day simple moving average is $43.89. SpringWorks Therapeutics has a 12-month low of $28.21 and a 12-month high of $62.00. The firm has a market cap of $3.53 billion, a price-to-earnings ratio of -13.73 and a beta of 0.70.